Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

MIXED(4)

OTHER(3)

finger prick screening for BBV infections and questionnaires by outreaching methodology

Determination of the economic burden NAFLD patients

1 trial

not_applicable

hasselt-university

Screening and studying characteristics

1 trial

not_applicable

ziekenhuis-oostlimburg

7 unique interventions2 categories

Analytics

Trial Phases

No phase data

Trial Status

Completed4

Other2

Role Distribution

Principal Investigator6

PI Rate100%

Activity Timeline

Clinical Trials (6)

NCT05035043Not ApplicableCompleted

Economic Burden of NAFLD

NAFLDNon-Alcoholic Fatty Liver Disease

PrincipalinvestigatorStart date: 2021-03-01

NCT04647409Not ApplicableActive Not Recruiting

Screening for NAFLD in Flanders

Non-Alcoholic Fatty Liver Disease

PrincipalinvestigatorStart date: 2020-10-26

NCT04999124Not ApplicableCompleted

Characteristics of NAFLD Among Type 2 Diabetes Patients

Non-Alcoholic Fatty Liver DiseaseType2 Diabetes

PrincipalinvestigatorStart date: 2020-01-01

NCT04251572Not ApplicableUnknown

HCV Reinfection After DAA Therapy in PWID in Belgium

Drug UseHepatitis C Virus Infection, Response to Therapy of

PrincipalinvestigatorStart date: 2019-07-01

NCT04363411Not ApplicableCompleted

Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections

Hepatitis BHepatitis cHuman Immunodeficiency Virus

PrincipalinvestigatorStart date: 2018-10-25

NCT03106194Not ApplicableCompleted

Case Management in HCV Infected PWID

Drug Abuse, Intravenous

PrincipalinvestigatorStart date: 2016-07-01

Research Network

Collaboration Network

5 collaborators·4 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Non-alcoholic Fatty Liver Disease3 Intravenous Drug Abuse1 Drug Use1 Hepatitis B1 Hepatitis C1 Hepatitis C Virus Infection, Response to Therapy of1 HIV1 Diabetes Mellitus, Type 21

Affiliations

Hasselt University

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Rob Bielen, dr.

Hasselt University

Similar

2 trials

Shared therapeutic areas:

Drug UseHepatitis BHepatitis C+2 more

Worked with same sponsors:

Algemeen Ziekenhuis Maria MiddelaresAlgemeen Ziekenhuis Vesalius+9 more

Collaborated on 2 trials

Similarity Score58%

Leen Heyens, drs.

Hasselt University

2 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2

Worked with same sponsors:

Hasselt UniversityZiekenhuis Oost-Limburg

Collaborated on 2 trials

Similarity Score28%

Rob Bielen, drs.

Hasselt University

1 trials

Shared therapeutic areas:

Intravenous Drug Abuse

Worked with same sponsors:

CAD LimburgHasselt University+1 more

Collaborated on 1 trial

Similarity Score14%

Leen Heyens

Hasselt University

1 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver Disease

Worked with same sponsors:

Hasselt University

Collaborated on 1 trial

Similarity Score14%

Mustafa H Temel, M.D.

Uskudar State Hospital

23 trials

Shared therapeutic areas:

Diabetes Mellitus, Type 2Hepatitis BHepatitis C

Similarity Score11%

Chen-Hua Liu, MD

National Taiwan University Hospital

14 trials

Shared therapeutic areas:

Hepatitis CHepatitis C Virus Infection, Response to Therapy ofHIV

Similarity Score11%

ali ismail, lecturer

Cairo University

29 trials

Shared therapeutic areas:

Hepatitis CDiabetes Mellitus, Type 2

Similarity Score8%

General Manager

Tanabe Pharma Corporation

28 trials

Shared therapeutic areas:

Diabetes Mellitus, Type 2Hepatitis B

Similarity Score8%

Samuel Klein, MD

Washington University School of Medicine

30 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2

Similarity Score8%

Eric Bellissant, MD, PhD

Rennes University Hospital

26 trials

Shared therapeutic areas:

Hepatitis BHepatitis C

Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT05035043Not ApplicablePrincipalInvestigator

Economic Burden of NAFLD

NAFLDNon-Alcoholic Fatty Liver Disease

Completed

NCT04647409Not ApplicablePrincipalInvestigator

Screening for NAFLD in Flanders

Non-Alcoholic Fatty Liver Disease

Active Not Recruiting

NCT04999124Not ApplicablePrincipalInvestigator

Characteristics of NAFLD Among Type 2 Diabetes Patients

Non-Alcoholic Fatty Liver DiseaseType2 Diabetes

Completed

NCT04251572Not ApplicablePrincipalInvestigator

HCV Reinfection After DAA Therapy in PWID in Belgium

Drug UseHepatitis C Virus Infection, Response to Therapy of

Unknown

NCT04363411Not ApplicablePrincipalInvestigator

Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections

Hepatitis BHepatitis cHuman Immunodeficiency Virus

Completed

NCT03106194Not ApplicablePrincipalInvestigator

Case Management in HCV Infected PWID

Drug Abuse, Intravenous

Completed

All 6 trials loaded